Mainz Stock Analysis

MYNZ -  USA Stock  

USD 27.76  7.51  37.09%

The current price rise of Mainz Biomed BV may encourage investors to take a closer look at the firm as it is trading at a share price of 27.76 on 515,165 in trading volume. The company executives may have good odds in positioning the firm resources to exploit market volatility in February. The stock standard deviation of daily returns for 90 days investing horizon is currently 16.96. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Mainz Biomed BV partners.
Additionally, see Stocks Correlation.

Mainz Stock Analysis 

 
Refresh
The Mainz Biomed stock analysis report makes it easy to digest most publicly released information about Mainz Biomed and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Mainz Stock analysis module also helps to analyze the Mainz Biomed price relationship with some important fundamental indicators such as market cap and management efficiency.

Mainz Stock Analysis Notes

The company had not issued any dividends in recent years. Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic tests for clinical diagnostics in the area of human genetics. The company was founded in 2008 and is based in Mainz, Germany. Mainz Biomed operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. To find out more about Mainz Biomed BV contact the company at 49 6131 554 2860 or learn more at https://mainzbiomed.com.

Mainz Biomed Quarterly Deferred Revenue

1,458Share

Mainz Biomed BV Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Mainz Biomed's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Mainz Biomed BV or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Mainz Biomed BV is way too risky over 90 days horizon
Mainz Biomed BV appears to be risky and price may revert if volatility continues
Latest headline from www.benzinga.com: Mid-Afternoon Market Update Dow Dips 500 Points NeuroMetrix Shares Spike Higher - Benzinga - Benzinga

Mainz Biomed SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Mainz Biomed prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Mainz Biomed investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Mainz Biomed BV specific information freely available to individual and institutional investors to make a timely investment decision.

Mainz Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 251.76 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Mainz Biomed's market, we take the total number of its shares issued and multiply it by Mainz Biomed's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Mainz Profitablity

Mainz Biomed's profitability indicators refer to fundamental financial ratios that showcase Mainz Biomed's ability to generate income relative to its revenue or operating costs. If, let's say, Mainz Biomed is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Mainz Biomed's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Mainz Biomed's profitability requires more research than a typical breakdown of Mainz Biomed's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(0.76) (0.82) 
Return on Average Equity 0.23  0.23 
Return on Invested Capital(0.36) (0.39) 
Return on Sales(0.96) (1.03) 

Management Efficiency

Return on Average Assets is likely to drop to -0.82 in 2022. Return on Invested Capital is likely to drop to -0.39 in 2022. Mainz Biomed Total Assets are fairly stable at the moment as compared to the past year. Mainz Biomed reported Total Assets of 605,943 in 2021. Current Assets is likely to rise to about 182.3 K in 2022, whereas Return on Average Assets are likely to drop (0.82)  in 2022. Mainz Biomed management efficiency ratios could be used to measure how well mainz biomed bv manages its routine affairs as well as how well it operates its assets and liabilities.
Last ReportedProjected for 2022
Book Value per Share(0.027) (0.0291) 
Tangible Assets Book Value per Share 0.0063  0.006474 
Tangible Asset Value605.9 K611.4 K

Technical Drivers

As of the 26th of January, Mainz Biomed secures the Mean Deviation of 9.27, risk adjusted performance of 0.1839, and Downside Deviation of 7.48. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Mainz Biomed BV, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to interpolate nineteen technical drivers for Mainz Biomed, which can be compared to its peers in the industry. Please verify Mainz Biomed BV treynor ratio, and the relationship between the variance and potential upside to decide if Mainz Biomed BV is priced some-what accurately, providing market reflects its recent price of 27.76 per share. Given that Mainz Biomed BV has jensen alpha of 3.57, we recommend you to check Mainz Biomed's last-minute market performance to make sure the company can sustain itself at a future point.

Mainz Biomed BV Price Movement Analysis

The output start index for this execution was one with a total number of output elements of fifty-five. The Simple Moving Average indicator is calculated by adding the closing price of Mainz Biomed for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Mainz Biomed BV short-term fluctuations and highlight longer-term trends or cycles. View also all equity analysis or get more info about simple moving average overlap studies indicator.

Mainz Biomed Technical and Predictive Indicators

Mainz Biomed Forecast Models

Mainz Biomed time-series forecasting models is one of many Mainz Biomed's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Mainz Biomed's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Mainz Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Mainz Biomed stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Mainz shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Mainz Biomed. By using and applying Mainz Stock analysis, traders can create a robust methodology for identifying Mainz entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(0.82) (0.88) 
Gross Margin 0.29  0.31 
Profit Margin(1.37) (1.48) 
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic tests for clinical diagnostics in the area of human genetics. The company was founded in 2008 and is based in Mainz, Germany. Mainz Biomed operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Mainz Biomed to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Price Ceiling Movement Now

   

Price Ceiling Movement

Calculate and plot Price Ceiling Movement for different equity instruments
All  Next Launch Module
Additionally, see Stocks Correlation. Note that the Mainz Biomed BV information on this page should be used as a complementary analysis to other Mainz Biomed's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Complementary Tools for Mainz Stock analysis

When running Mainz Biomed BV price analysis, check to measure Mainz Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mainz Biomed is operating at the current time. Most of Mainz Biomed's value examination focuses on studying past and present price action to predict the probability of Mainz Biomed's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Mainz Biomed's price. Additionally, you may evaluate how the addition of Mainz Biomed to your portfolios can decrease your overall portfolio volatility.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is Mainz Biomed's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mainz Biomed. If investors know Mainz will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mainz Biomed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Mainz Biomed BV is measured differently than its book value, which is the value of Mainz that is recorded on the company's balance sheet. Investors also form their own opinion of Mainz Biomed's value that differs from its market value or its book value, called intrinsic value, which is Mainz Biomed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mainz Biomed's market value can be influenced by many factors that don't directly affect Mainz Biomed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mainz Biomed's value and its price as these two are different measures arrived at by different means. Investors typically determine Mainz Biomed value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mainz Biomed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.